TW200600098A - Solid orally ingestible formulations of tetrodotoxin - Google Patents

Solid orally ingestible formulations of tetrodotoxin

Info

Publication number
TW200600098A
TW200600098A TW094120655A TW94120655A TW200600098A TW 200600098 A TW200600098 A TW 200600098A TW 094120655 A TW094120655 A TW 094120655A TW 94120655 A TW94120655 A TW 94120655A TW 200600098 A TW200600098 A TW 200600098A
Authority
TW
Taiwan
Prior art keywords
tetrodotoxin
orally ingestible
solid orally
ingestible formulations
formulations
Prior art date
Application number
TW094120655A
Other languages
English (en)
Inventor
Wei-Yang Lin
Claude Cardinal
Frank Haykong Shum
Original Assignee
Wex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35481453&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200600098(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wex Pharmaceuticals Inc filed Critical Wex Pharmaceuticals Inc
Publication of TW200600098A publication Critical patent/TW200600098A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW094120655A 2004-06-22 2005-06-21 Solid orally ingestible formulations of tetrodotoxin TW200600098A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/872,528 US20050282836A1 (en) 2004-06-22 2004-06-22 Solid orally ingestible formulations of tetrodotoxin

Publications (1)

Publication Number Publication Date
TW200600098A true TW200600098A (en) 2006-01-01

Family

ID=35481453

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094120655A TW200600098A (en) 2004-06-22 2005-06-21 Solid orally ingestible formulations of tetrodotoxin

Country Status (8)

Country Link
US (1) US20050282836A1 (zh)
EP (1) EP1765353A1 (zh)
CN (1) CN1972689A (zh)
AR (1) AR049698A1 (zh)
CA (1) CA2570709A1 (zh)
PE (1) PE20060460A1 (zh)
TW (1) TW200600098A (zh)
WO (1) WO2005123088A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2808282C (en) * 2010-08-25 2018-06-05 Qihui Jessica Zhu Improved enteric active substance delivery
CN105919979B (zh) * 2016-06-28 2019-07-02 国家海洋局第三海洋研究所 一种替曲朵辛肠溶缓释微丸、制备方法及其应用
CN106063780B (zh) * 2016-06-28 2019-08-02 自然资源部第三海洋研究所 一种替曲朵辛速释微丸制剂、制备方法及其应用
CN107349206A (zh) * 2017-07-11 2017-11-17 东新皓特（北京）生化科技有限公司 河豚毒素在制备治疗新型毒品不良症状及复吸的药物组合物中的应用
CN107198689A (zh) * 2017-07-11 2017-09-26 东新皓特（北京）生化科技有限公司 用于治疗疼痛病症的河豚毒素药物组合物及外用药
CN107308166A (zh) * 2017-07-11 2017-11-03 东新皓特（北京）生化科技有限公司 河豚毒素在制备治疗前列腺病症药物组合物中的应用、药物组合物及制备方法
CN107349205A (zh) * 2017-07-11 2017-11-17 东新皓特（北京）生化科技有限公司 河豚毒素在制备治疗犬瘟热的药物组合物中应用、药物组合物、制备方法及药物制剂
CN107349314A (zh) * 2017-07-11 2017-11-17 东新皓特（北京）生化科技有限公司 河豚毒素在制备治疗中老年人性功能减退病症药物组合物中的应用、及药物组合物
CN107349204A (zh) * 2017-07-11 2017-11-17 东新皓特（北京）生化科技有限公司 河豚毒素在制备治疗带状疱疹病症药物组合物中的应用、药物组合物及外用药
CN112704665A (zh) * 2021-01-08 2021-04-27 江苏宏锦天药业有限公司 替曲朵辛口服制剂、替曲朵辛冻干片及其应用
CN115475151A (zh) * 2022-08-14 2022-12-16 中国人民解放军海军军医大学 河豚毒素缓释微球及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2168331C2 (ru) * 1994-03-17 2001-06-10 Наннинь Мапле Лиаф Фармацевтикал Ко., Лтд. Применение соединений аминогидрогенизированного хиназолина и их производных для лечения наркотической зависимости
AU6883798A (en) * 1997-04-02 1998-10-22 Regents Of The University Of California, The Method of anesthesia
CN1085532C (zh) * 1998-06-09 2002-05-29 河北省水产研究所 一种戒除药物依赖性的药剂
CN1284536C (zh) * 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1382443A (zh) * 2001-04-25 2002-12-04 威克斯医疗仪器有限公司 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用
CN100360133C (zh) * 2002-05-23 2008-01-09 潘心富 用于戒毒、镇痛的河豚毒素呼吸道给药制剂

Also Published As

Publication number Publication date
CN1972689A (zh) 2007-05-30
PE20060460A1 (es) 2006-06-02
EP1765353A1 (en) 2007-03-28
AR049698A1 (es) 2006-08-30
WO2005123088A1 (en) 2005-12-29
CA2570709A1 (en) 2005-12-29
US20050282836A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
TW200600098A (en) Solid orally ingestible formulations of tetrodotoxin
FR22C1027I1 (fr) Formulations stabilisant et inhibant la précipitation de compositions immunogènes
WO2008066899A3 (en) Nanoparticulate formulations and methods for the making and use thereof
HK1119951A1 (zh) 蛋白質的口服方法及成分
WO2009114118A3 (en) Oral pharmaceutical compositions of buprenorphine and method of use
SG153800A1 (en) Pharmaceutical compositions
AU2003280087A1 (en) Dosage forms for increasing the solubility and extending the release of drugs such as e.g. topiramate and phenyton
EP1578403A4 (en) MODIFIED RELEASE MILNACIPRANE COMPOSITIONS
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
IL198513A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
WO2007109604A3 (en) Pharmaceutical compositions
HK1076605A1 (en) Formulations
AP2714A (en) Orodispersible pharmaceutical composition for or omucosal or sublingual administration of agomelati ne
MX2010005175A (es) Comprimido dispersable oral.
AP2008004447A0 (en) Orally absorbed pharmaceutical formulation and method of administration
HK1107271A1 (en) Method of enhancing absorptions of transmucosal administration formulations
EP1895991A4 (en) MODIFIED RELEASE FORMULATIONS OF ANTI-IRRITABLE DRUGS
IL180031A0 (en) Stable pharmaceutical formulations of benzimidazole compounds
MY150829A (en) Oral compositions containing extracts of myristica fragrans and related methods
DK1837019T3 (da) Orale dispergerbare farmaceutiske sammensætninger
WO2007095091A3 (en) Oral delivery of therapeutic agents using tight junction agonists
WO2008054808A3 (en) Elvucitabine pharmaceutical compositions
NO20034139L (no) Faste oralt dispergerbare farmasöytiske formuleringer
EP2196463A4 (en) PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, DERIVATIVES DERIVATED THEREOF AND PHARMACEUTICAL FORMULATIONS THEREOF
EP1556024A4 (en) INTERMITTENT LIBERATION COMPOSITIONS OF MILNACIPRANE